Comparative study of the efficacy of potassium magnesium L-, D- and DL-aspartate stereoisomers in overcoming digoxin- and furosemide-induced potassium and magnesium depletions

Magnesium Research

Volumn 17, Issue 4, 2004, Pages 276-292

  Iezhitsa, I N ^a   Spasov, A A ^a   Zhuravleva, N V ^a   Sinolitskii, M K ^b   Voronin, S P ^b  

^a VOLGOGRAD STATE MEDICAL UNIVERSITY   (Russian Federation)

^b BioAmid   (Russian Federation)

Author keywords

D and DL isomers of aspartic acid; Digoxin; Furosemide; L ; Potassium and magnesium aspartate; Potassium and magnesium deficiencies; Rat

Indexed keywords

AMINE; ASPARTIC ACID DERIVATIVE; DEXTRO ASPARTIC ACID; DIGOXIN; FUROSEMIDE; NINHYDRIN; NITROGEN; POTASSIUM MAGNESIUM ASPARTATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BODY WEIGHT; COLORIMETRY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; ERYTHROCYTE; FLAME PHOTOMETRY; HEART MUSCLE; HEMOCONCENTRATION; INTERMETHOD COMPARISON; MAGNESIUM DEFICIENCY; MAGNESIUM DEPLETION; MALE; NONHUMAN; POTASSIUM DEFICIENCY; POTASSIUM DEPLETION; QUANTITATIVE ANALYSIS; RAT; REACTION ANALYSIS; STAINING; STEREOISOMERISM; URINARY EXCRETION;

AMINES; ANIMALS; DIGOXIN; ERYTHROCYTES; FUROSEMIDE; MAGNESIUM; MALE; MYOCARDIUM; POTASSIUM; POTASSIUM MAGNESIUM ASPARTATE; RATS; STEREOISOMERISM;

ANIMALIA;

EID: 12744263416     PISSN: 09531424     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Vierling W. Bemerkungen zur Kinetic und zu extrazellularen Wirkungen von Kalium und Magnesium. Herz 1997; 22: 3-10; (German).
2. Bara M, Guiet-Bara A, Durlach J. Regulation of sodium and potassium pathways by magnesium in cell membranes. Magnes Res 1993; 6: 167-77.
3. Elisaf M, Liberopoulos E, Bairaktari E, Siamopoulos K. Hypokalaemia in alcoholic patients. Drug Alcohol Rev 2002; 21: 73-6.
4. Elisaf M, Merkouropoulos M, Tsianos EV, Siamopoulos KC. Pathogenetic mechanisms of hypomagnesemia in alcoholic patients. J Trace Elem Med Biol 1995; 9: 210-4.
5. Flink EB. Magnesium deficiency in alcoholism. Alcohol Clin Exp Res 1986; 10: 590-4.
6. Holzbach E. Reversible Hypokaliamie und Hypomagnesiamie während des Alkoholentzugssyndroms. Nervenarzt 1994; 65: 206-11; (German).
7. Ragland G. Electrolyte abnormalities in the alcoholic-patient. Emerg Med Clin North Am 1990; 8: 761-73.
8. Touitou Y, Godard JP, Ferment O, Chastang C, Proust J, Bogdan A, Auzeby A, Touitou C. Prevalence of magnesium and potassium deficiencies in the elderly. Clin Chem 1987; 33: 518-23.
9. Wazny LD, Brophy DF. Amiloride for the prevention of amphotericin B-induced hypokalemia and hypomagnesemia. Ann Pharmacother 2000; 34: 94-7.
10. Kes P, Reiner Z. Symptomatic hypomagnesemia associated with gentamicin therapy. Magnes Trace Elem 1990; 9: 54-60.
11. Nanji AA, Denegri JF. Hypomagnesemia associated with gentamicin therapy. Drug Intell Clin Pharm 1984; 18: 596-8.
12. Bianchetti MG, Kanaka C, Ridolfi-Luthy A, Wagner HP, Hirt A, Paunier L, Peheim E, Oetliker OH. Chronic renal magnesium loss, hypocalciuria and mild hypokalaemic metabolic alkalosis after cisplatin. Pediatr Nephrol 1990; 4: 219-22.
13. Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev 1999; 25: 47-58.
14. Crippa G, Sverzellati E, Giorgi-Pierfranceschi M, Carrara GC. Magnesium and cardiovascular drugs: interactions and therapeutic role. Ann Ital Med Int 1999; 14: 40-5.
15. Berkelhammer C, Bear RA. A clinical approach to common electrolyte problems: 4. Hypomagnesemia. Can Med Assoc J 1985; 132: 360-8.
16. Luderitz B. Potassium deficiency and cardiac function: experimental and clinical aspects. Magnesium 1984; 3: 289-300.
17. Martin BJ, McAlpine JK, Devine BL. Hypomagnesaemia in elderly digitalised patients. Scott Med J 1988; 33: 273-4.
18. Ryan MP. Interrelationships of magnesium and potassium homeostasis. Miner Electrolyte Metab 1993; 19: 290-5.
19. Young IS, Goh EM, McKillop UH, Stanford CF, Nicholls DP, Trimble ER. Magnesium status and digoxin toxicity. Br J Clin Pharmacol 1991; 32: 717-21.
20. Leary WP, Reyes AJ. Diuretics, magnesium, potassium and sodium. S Afr Med J 1982; 61: 279-80.
21. Greenberg A. Diuretic complications. Am J Med Sci 2000; 319: 10-24.
22. Swales JD. Magnesium deficiency and diuretics. Br Med J (Clin Res Ed) 1982; 285: 1377-8.
23. Robertson JI. Diuretics, potassium depletion and the risk of arrhythmias. Eur Heart J 1984; 5: 25-8.
24. Wester PO, Dyckner T. Problems with potassium and magnesium in diuretic-treated patients. Acta Pharmacol Toxicol 1984; 54: 59-65; (Copenh.).
25. Dørup I, Clausen T. Effects of potassium deficiency on growth and protein synthesis in skeletal muscle and the heart of rats. Br J Nutr 1989; 62: 269-84.
26. Dørup I, Clausen T. Effects of magnesium and zinc deficiencies on growth and protein synthesis in skeletal muscle and the heart. Br J Nutr 1991; 66: 493-504.
27. Dørup I, Flyvbjerg A, Everts ME, Clausen T. Role of insulin-like growth factor I and growth hormone in growth inhibition induced by magnesium and zinc deficiencies. Br J Nutr 1991; 66: 505-21.
28. Dørup I. Magnesium and potassium deficiency; its diagnosis, occurrence and treatment in diuretic therapy and its consequences for growth, protein synthesis and growth factors. Acta Physiol Scand 150, 1-55.
29. Tveskov C, Djurhuus MS, Klitgaard NA. Heart rate disorders in potassium and magnesium deficiency. Ugeskr Laeger 1992; 154: 2470-4; (Danish).
30. Schwinger RH, Erdmann E. Heart failure and electrolyte disturbances. Methods Find Exp Clin Pharmacol 1992; 14: 315-25.
31. Sheehan JP, Seelig MS. Interactions of magnesium and potassium in the pathogenesis of cardiovascular disease. Magnesium 1984; 3: 301-14.
32. Whang R. Magnesium and potassium interrelationships in cardiac arrhythmias. Magnesium, 1986; 5: 127-33.
33. Durlach J, Collery P. Magnesium and potassium in diabetes and carbohydrate metabolism. Review of the present status and recent results. Magnesium 1984; 3: 315-23.
34. Sjögren A, Florén CH, Nilsson Å. Magnesium, potassium and zinc deficiency in subjects with type II diabetes mellitus. Acta Med Scand 1988; 224: 461-6.
35. Hansen KW, Mosekilde L. Gitelman syndrome. An overlooked disease with chronic hypomagnesemia and hypokalemia in adults. Ugeskr Laeger 2003; 165: 1123-7; (Danish).
36. Warnock DG. Genetic forms of renal potassium and magnesium wasting. Am J Med 2002; 112: 235-6.
37. Aksel'ro LB, Arshinova LS, Gaidenko AI, Makshnovich IB, Sukolovskaia DM. Comparative evaluation of cardiotropic effects of nicamag, panangin and asparkam. Farmakol Toksikol 1985; 48: 51-5; (Russian).
38. Berliand AS, Krylov IF, Muliar AG, Mutin IN, Sevriugina II. A preclinical evaluation of the pharmacological activity of a mixed potassium and magnesium glutamate. Eksp Klin Farmakol 1997; 60: 16-9; (Russian).
39. Kamshilova EA. Treatment of cardiac rhythm disorders with panangin. Kardiologiia 1973; 13: 104-9; (Russian).
40. Kühn P, Oberthaler G, Oswald J. Antiarrhythmische Wirksamkeit von Kalium-Magnesium-Aspartat-Infusion. Wien Med Wochenschr 1991; 141: 64-5; (German).
41. Lautsevichus LZ, Kibarskis KK, Moteiunaite ES. Use of panangin in cardiac insufficiency and rhythm disorders. Vrach Delo 1972; 4: 30-3; (Russian).
42. Markiewicz M, Korolko A. Clinical assessment of Cardilan. Pol Tyg Lek 1970; 25: 1816-7; (Polish).
43. Pak CY. Correction of thiazide-induced hypomagnesemia by potassium-magnesium citrate from review of prior trials. Clin Nephrol 2000; 54: 271-5.
44. Ruml LA, Gonzalez G, Taylor R, Wuermser LA, Pak CY. Effect of varying doses of potassium-magnesium citrate on thiazide-induced hypokalemia and magnesium loss. Am J Ther 1999; 6: 45-50.
45. Nieper HA, Blumberger KJ. Experimental basis and clinical use of electrolyte carrier compounds. I. Metabolic activity of Mg- and K-asparaginate, especially in coronary insufficiency. Arztl Forsch 1961; 15: 125-30.
46. Nieper HA, Blumberger K. Wirkung von Elekrolytschlepper-Verbindungen (K-Mg-Asparaginat) auf den Herzstoffwechsel. Verh Dtsch Ges Kreislaufforsch 1961; 27: 238-42; (German).
47. Labori H. New physiologic concepts of cardiovascular functions. Therapeutic consequences. In: Bajusz E, ed. Electrolytes and cardiovascular diseases, vol 2. 1966: 239-59.
48. Laborit H. Les régulations métaboliques: aspects théorique, expérimental, pharmacologique et thérapeutique. France: Masson, 1966; (French).
49. Laborit H, Weber B. Protective effect of potassium and magnesium salts of DL-aspartic acid against convulsions caused by isoniazid and ammonium chloride in the rat. Psychopharmacologia 1959; 1: 79-88; (French).
50. Laborit H, Moynier R, Coirault R, Thiebault J, Guiot G, Niaussat P, Weber B, Jouany JM, Baron C. The place of certain salts of DL-aspartic acid in the mechanisms of preservation of activity in reaction to the environment; summary of an experimental and clinical study. Presse Med 1958; 66: 1307-9; (French).
51. Laborit H, Obrenovitch L, Leguen P. Changes in blood ammonia in swimming test in white rats; effects of potassium and magnesium salts of DL-aspartic acid. CR Seances Soc Bio Fil 1958; 152: 1359-60; (French).
52. Laborit H, Obrenovitch L, Leguen P, Jouany JM. Effects of potassium & magnesium salts of DL-aspartic acid on the hyperammoniemia of experimental hemorrhagic shock. C R Seances Soc Biol Fil 1958; 152: 942-4; (French).
53. Michon P, Larcan A, Huriet C, Streiff F, Tapin M. The use of a potassium and magnesium aspartate in the treatment of myocardial infarction. Therapie 1962; 17: 947-66; (French).
54. Melon JM. Clinical trials of potassium aspartate and magnesium aspartate in cardiovascular diseases. Agressologie 1960; 1: 443-54.
55. Nakahara M, Yoshihara T, Tokita T, Nakanishi Y, Sakahashi H, Shibata N. Difference in action between D- and L-potassium and magnesium aspartates. Arzneimittelforschung 1966; 16: 1491-4.
56. Pach J, Targosz D, Kamenczak A. The usefulness of Aspargin for supplementing potassium and magnesium in ethanol dependent patients. Przegl Lek 1999; 56: 472-4; (Polish).
57. Corrigan JJ. D-amino acids in animals. Science 1969; 164: 142-9.
58. Oguri S, Kumazaki M, Kitou R, Nonoyama H, Tooda N. Elucidation of intestinal absorption of D-amino acid enantiomers and aging in rats. Biochim Biophys Acta 1999; 1472: 107-14.
59. Nagata Y, Konno R, Yasumura Y, Akino T. Involvement of D-amino acid oxidase in elimination of free D-amino acids in mice. Biochem J 1989; 257: 291-2.
60. D'Aniello A, D'Onofrio G, Pischetola M, D'Aniello G, Veteve A, Petrucelli L, Fischer GH. Biological role of D-amino acid oxidase and D-aspartate oxidase. Effects of D-amino acids. J Biol Chem 1993; 268: 26941-9.
61. Dunlop DS, Neidle A, McHale D, Dunlop DM, Lajtha A. The presence of free D-aspartic acid in rodents and man. Biochem Biophys Res Commun 1986; 141: 27-32.
62. Hashimoto A, Kumashiro S, Nishikawa T, Oka T, Takahashi K, Mito T, Takashima S, Doi N, Mizutani Y, Yamakazi T, Kaneko T, Ootomo E. Embryonic development and postnatal changes in free D-aspartate and D-serine in the human prefrontal cortex. J Neurochem 1993; 61: 348-51.
63. Fisher GH, Petrucelli L, Gardner C, Emory C, Frey WH Jr, Amaducci L, Sorbi S, Sorrentino G, Borghi M, D'Aniello A. Free D-amino acids in human cerebrospinal fluid of Alzheimer disease, multiple sclerosis, and healthy control subjects. Mol Chem Neuropathol 1994; 23: 115-24.
64. Hashimoto A, Oka T, Nishikawa T. Anatomical distribution and postnatal changes in endogenous free D-aspartate and D-serine in rat brain and periphery. Eur J Neurosci 1995; 7: 1657-63.
65. Imai K, Fukushima T, Hagiwara K, Santa T. Occurrence of D-aspartic acid in rat brain pineal gland. Biomed Chromatogr 1995; 9: 106-9.
66. Imai K, Fukushima T, Santa T, Homma H, Huang Y, Sakai K, Kato M. Distribution of free D-amino acids in tissues and body fluids of vertebrates. Enantiomer 1997; 2: 143-5.
67. Imai K, Fukushima T, Santa T, Homma H, Hamase K, Sakai K, Kato M. Analytical chemistry and biochemistry of D-amino acids. Biomed Chromatogr 1996; 10: 303-12.
68. Schieber A, Brückner H, Rupp-Classen M, Specht W, Nowitzki-Grimm S, Classen HG. Evaluation of D-amino acid levels in rat by gas chromatography- selected ion monitoring mass spectrometry: no evidence for subacute toxicity of orally fed D-proline and D-aspartic acid. J Chromatogr B Biomed Sci Appl 1997; 691: 1-12.
69. Durlach J, Pagès N, Bac P, Bara M, Guiet-Bara A. Beta-2 mimetics and magnesium: true or false friends? Magnes Res 2003; 16: 218-33.
70. Durlach J, Bara M, Theophanides T. A hint on pharmacological and toxicological differences between magnesium chloride and magnesium sulphate, or of scallops and men. Magnes Res 1996; 9: 217-9.
71. Spasov AA, Iezhitsa IN, Zhuravleva NV, Gurova NA. Comparative study of antiarrhythmic activity of L-, D-and DL-stereoisomers of potassium magnesium asparaginate. Proceedings of VI Cardiostim Pan Slavic-International Congress on Cardiac Pacing and Electrophysiology; VIII Russian Symposium on Cardiac Pacing and Electrophysiology; VI Russian Symposium "Diagnosis and therapy of arrhythmias in children"; IV International Symposium "Electronics in Medicine. Monitoring, Diagnosis, Therapy". St.-Petersburg. February 5-7th, 2004, Post 319. J Arrhythmology 2004; 35: 114; (Russian).
72. Kolb VG. Clinical biochemistry (the handbook for physicians). Minsk: Publisher "Minsk", 1976; (Russian).
73. Men'shikov VV. Laboratory methods of clinic testings. Moscow: Publisher "Meditsina", 1987; (Russian).
74. Flatman PW, Almulla H, Ellis D. The role of sodium-magnesium antiport in magnesium homeostasis in the mammalian heart. In: Rayssiguier Y, Mazur A, Durlach J, eds. Advances in magnesium research: nutrition and health. Vichy, France: John Libbey & Company Ltd, 2000: 39-45.
75. Borchgrevink PC, Holten T, Jynge P. Tissue electrolyte changes induced by high doses of diuretics in rats. Pharmacol Toxicol 1987; 60: 77-80.
76. Borchgrevink PC, Jynge P. Prolonged diuretic administration and myocardial tolerance to ischaemia. Pharmacol Toxicol 1987; 61: 254-9.
77. Greger R. Ion transport mechanism in thick ascending limb of Henle's loop of mammalian nephron. Physiol Rev 1985; 65: 760-97.
78. Quamme GA. Effect of furosemide on calcium and magnesium transport in the rat nephron. Am J Physiol 1981; 241: F340-F347.